Unia Europejska - estoński - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - sclerosis multiplex, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Estonia - estoński - Ravimiamet

g.l. pharma gmbh - fingolimood - kõvakapsel - 0,5mg 10tk; 0,5mg 28tk; 0,5mg 60tk; 0,5mg 30tk; 0,5mg 98tk; 0,5mg 7tk

Estonia - estoński - Ravimiamet

teva gmbh - fingolimood - kõvakapsel - 0,5mg 10tk; 0,5mg 98tk; 0,5mg 28tk; 0,5mg 100tk; 0,5mg 30tk

Estonia - estoński - Ravimiamet

medochemie limited - fingolimood - kõvakapsel - 0,5mg 98tk; 0,5mg 28tk; 0,5mg 7tk; 0,5mg 10tk; 0,5mg 30tk

Estonia - estoński - Ravimiamet

krka, d.d., novo mesto - fingolimood - kõvakapsel - 0,5mg 60tk; 0,5mg 30tk; 0,5mg 98tk; 0,5mg 28tk; 0,5mg 14tk; 0,5mg 90tk; 0,5mg 100tk

Estonia - estoński - Ravimiamet

gedeon richter plc. - fingolimood - kõvakapsel - 0,5mg 7tk; 0,5mg 98tk; 0,5mg 28tk

Estonia - estoński - Ravimiamet

stada arzneimittel ag - fingolimood - kõvakapsel - 0,5mg 7tk; 0,5mg 28tk; 0,5mg 30tk

Estonia - estoński - Ravimiamet

remedica limited - fingolimood - kõvakapsel - 0,5mg 98tk; 0,5mg 28tk; 0,5mg 7tk

Estonia - estoński - Ravimiamet

norameda uab - fingolimood - kõvakapsel - 0,5mg 28tk; 0,5mg 98tk; 0,5mg 100tk

Estonia - estoński - Ravimiamet

zentiva k.s. - fingolimood - kõvakapsel - 0,5mg 28tk; 0,5mg 30tk; 0,5mg 7tk; 0,5mg 56tk